EBO.NZ
BuyUnloved QualityAI neutralEBOS Group Limited · Healthcare · Australia · $2.3B
NZD 19.14 +3.5% · close 6 Oct · scored 7 Oct
StockRank up 2.0 since 6 Oct.
Unloved Quality: Strong and cheap; the market has not turned yet.
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
EBOS distributes pharmaceuticals and medical products across Australia and New Zealand and owns an animal-care business. Healthcare distribution is defensive and scale matters, but margins are thin and the loss of the Chemist Warehouse wholesale contract hurt revenue. Growth depends on acquisitions and the animal-care segment, and there is no clear sign of acceleration.
ABOUT EBOS GROUP LIMITED
Read
EBOS Group Limited engages in the marketing, wholesale, and distribution of healthcare, medical, pharmaceutical, and animal care products in Australia, Southeast Asia, and New Zealand. It operates through Healthcare and Animal Care segments.
FINANCIAL SUMMARY (NZD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 14.8B | 16.5B | 17.9B | 16.4B | 3.5% | 29.8B | 17.1B | 17.8B | 2.8% |
| EPS (NZD) | 1.58 | 1.80 | 1.92 | 1.47 | -2.4% | 1.33 | 1.45 | 1.62 | 3.4% |
| Shares | 189.4M | 191.6M | 193.2M | 203.2M | +7.3% | 207.0M | — | — | — |
| Debt | 2.3B | 1.7B | 2.2B | 2.2B | -1.5% | 4.2B | — | — | — |
| Equity | 3.1B | 3.3B | 3.3B | 3.7B | 5.5% | — | — | — | — |
| Op CF | 342.7M | 529.2M | 472.8M | 559.9M | 17.8% | 771.8M | — | — | — |
| Inv CF | -1.9B | -208.6M | -513.3M | -493.5M | — | — | — | — | — |
| Fin CF | 2.1B | -739.8M | 46.6M | -113.6M | — | — | — | — | — |
Calmer than 80% of stocks we rank over the past year (26% a year).
How this is worked out
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of EBO.NZ are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| EBO.NZ | EBOS Group Limited(you) | $2.3B | 75 | Buy |
| MYX.AX | Mayne Pharma Group Limited | $168M | 72 | Buy |
| SIG.AX | Sigma Healthcare Limited | $21.0B | 58 | Hold |
| PGC.AX | Paragon Care Limited | $163M | 57 | Hold |
| NEU.AX | Neuren Pharmaceuticals Limited | $1.8B | 60 | Hold |
| REG.AX | Regis Healthcare Limited | $996M | 64 | Hold |
| RHC.AX | Ramsay Health Care Limited | $9.0B | 73 | Buy |
| IDX.AX | Integral Diagnostics Limited | $588M | 79 | Buy |
| SHL.AX | Sonic Healthcare Limited | $6.6B | 87 | Strong Buy |
| ANN.AX | Ansell Limited | $4.3B | 97 | Strong Buy |
Peer medians: ROE -22.0% · P/E 35.8x · Gross margin 62.8%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.